Jubilant Pharmova Ltd Stock Analysis

BSE: 530019 | NSE: JUBLPHARMA | Pharmaceuticals & Drugs | Mid Cap

BSE Share Price Jul 04, 09:37
343.50 4.80 (1.42%)

DeciZen - Make an Informed Decision on Jubilant Pharmova

Overall Rating

1. Quality

2. Valuation


3. Price Trend


1. Is Jubilant Pharmova Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Jubilant Pharmova Ltd is a average quality company.

2. Is Jubilant Pharmova Ltd undervalued or overvalued?

The key valuation ratios of Jubilant Pharmova Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Jubilant Pharmova Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Jubilant Pharmova Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Jubilant Pharmova:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Jubilant Pharmova Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 3.8%4.6%7.1%4.6%5.8%5.4%9.5%6.6%9.8%9%-
Value Creation Index -0.7-0.7-0.5-0.7-0.6-0.6-0.3-0.5-0.3-0.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 2,6413,1463,6733,1762,6562,4913,3063,4393,1402,71088
YoY Gr. Rt. %-19.1%16.7%-13.5%-16.4%-6.2%32.7%4%-8.7%-13.7%-
Adj EPS 3.32.810.
YoY Gr. Rt. %--16.6%263.5%-68.3%85%-14.1%217.2%-35.8%99.4%-34.6%-
BVPS (₹) 120.4115.8112.2122.1126.4128.2141.2146.9163.780.580.5
Adj Net Profit 52.944.116050.99480.725616532821579
Cash Flow from Ops. 406827549286164419558182317608-
Debt/CF from Ops. 7.23.968114.


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 0.3%0.4%-6.4%-13.7%
Adj EPS 16.9%18%-5.7%-34.6%
BVPS -4.4-8.6-17.1-50.8
Share Price 7.1% -13.1% -11.5% -52.5%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % 2.62.392.84.8411.97.213.3116.1
Op. Profit Mgn % 16.315.616.18.912.913.216.41012.115.8-7.7
Net Profit Mgn %
Debt to Equity
Working Cap Days 216202188216195154133139161102150
Cash Conv. Cycle 7657444740442328412432

Recent Performance Summary

Debt to equity has declined versus last 3 years average to 0.38

Return on Equity has declined versus last 3 years average to 6.10%

Sales growth has been subdued in last 3 years -6.42%

Net Profit has been subdued in last 3 years -5.71%

Sales growth is not so good in last 4 quarters at -96.12%

Latest Financials - Jubilant Pharmova Ltd.

Standalone Consolidated
TTM EPS (₹) 4.9 26
TTM Sales (₹ Cr.) 87.8 6,059
BVPS (₹.) 80.5 333.9
Reserves (₹ Cr.) 1,266 5,303
P/BV 4.21 1.02
PE 68.72 13.10
From the Market
52 Week Low / High (₹) 317.65 / 766.85
All Time Low / High (₹) 3.51 / 1046.75
Market Cap (₹ Cr.) 5,395
Equity (₹ Cr.) 15.9
Face Value (₹) 1
Industry PE 30.7

Management X-Ray of Jubilant Pharmova :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Login/Register to view analysis.


About Jubilant Pharmova Ltd

Jubilant Life Sciences (formerly Jubilant Organosys) was incorporated in the year 1978. It’s a public limited company domiciled in India and incorporated under the provisions of Companies Act, 1956. Its shares are listed on BSE Limited and National Stock Exchange of India Limited.

The Pharmaceuticals segment, through its wholly-owned subsidiary Jubilant Pharma Limited, is engaged in manufacturing and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six USFDA approved manufacturing facilities in the US, Canada and India and a network of various radiopharmacies in the US.

The Life Science Ingredients segment is engaged in specialty intermediates, nutritional products and life science chemicals through five manufacturing facilities in India. The drug discovery solutions business is served by Jubilant Biosys and the India branded pharmaceuticals business is an Indian venture with a range of pharmaceutical offerings for the domestic market, focusing primarily on products to treat medical conditions in the field of cardiology and diabetology.

Business area of the company

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients, drug discovery solutions and India branded pharmaceuticals.

Business segments

  • Pharmaceuticals
  • Life Science Ingredients
  • Drug Discovery & Development Solutions
  • India Branded Pharmaceuticals



  • NDTV Profit Business Leadership Award 2012 for Corporate Social Responsibility. National Quality Excellence Award for best in Class manufacturing presented by Stars of the Industry Group.CII ‘National Award for Excellence in Water Management 2012’ as ‘Water Efficient Unit’ for Gajraula Unit.
  • Economic Times - Frost & Sullivan India Manufacturing Excellence Gold Award - Process Sector for 2012. I.C.C. Award for Water Resource Management in Chemical Industry for the year 2011.


  • Jubilant Life Sciences Awarded ‘Excellence Award’ by Export Promotion Bureau.
  • Jubilant Life Sciences declared winner of ‘Supply Chain Excellence Awards’ at 7th Express, Logistics & Supply Chain Leadership Awards 2013.
  • Jubilant Life Sciences receives prestigious NDTV Profit Business Leadership Award 2012 for Corporate ‘Social Responsibility’.


  • Jubilant Life Sciences wins Excellence Awards at ‘India Pharma Awards’ 2014.
  • BRI Partners with Jubilant Life Sciences to Bring XylamaxTM to the South Asia Poultry Market.
  • Jubilant Life Sciences conferred with Golden Peacock Business Excellence Award-2014.
  • Jubilant Biosys and Orion Corporation Announces Unique Collaborative Discovery Program in Pain Management Area.
  • IDRI and Jubilant Chemsys Extend Research for TB Drug Discovery.
  • Jubilant Life Sciences declared winner of 'Bio Excellence Award 2014' at Bangalore India Bio 2014.
  • Jubilant Biosys Announces Expansion of Drug Discovery Alliance with Janssen Pharmaceutical.


  • Jubilant Life Sciences conferred with Golden Peacock National Quality Award.
  • Jubilant Life Sciences wins ASSOCHAM’s ‘Responsible Organization Excellence’ Award 2014-15.


  • Sustainability Award for Best Green Process in ‘Chemical Sector’ by ‘FICCI Chemicals & Petrochemicals Awards, 2016’.
  • Winner of two CHEMEXCIL Export Awards: Trishul Export Award 2012-13 and Gold Export Award 2011-12.
  • 16th Annual Greentech Environment Award 2015 (Gold Category), conferred under ‘Chemicals and Pharmaceutical sector’ - Gajraula plant, India.


  • Social Entrepreneur of the Year (SEOY)-India Award 2017.
  • Finalists for Social Entrepreneur of the Year (SEOY) India 2017 Award.
  • ‘Second Awards’ under the category of Basic Inorganic, Organic Chemicals including Agro Chemicals for the outstanding export performance of the year 2015-16 by CHEMEXCIL.
Read More Read Less